Growth hormone biomarkers are not a substitute for functional outcomes

MK-677, CJC-1295 and ipamorelin are discussed together because of their relationships to growth-hormone signaling. They are not the same molecule or the same intervention. MK-677 is a non-peptide secretagogue, while the other compounds have different structures and pharmacological profiles.

A randomized study of MK-677 in older adults found increased fat-free mass without demonstrated improvement in strength or function. This is a useful reminder that changing a hormone axis or body-composition measure does not automatically improve how a person feels or performs. MK 677 randomized trial in older adults

Compare endpoints before compounds

An experiment measuring growth hormone over hours answers a different question from a trial measuring mobility over months. A claim about recovery, sleep or muscle should be supported by a study that actually assessed that outcome in a relevant population.

The setting also matters. Results in older adults or hospitalized patients cannot be assumed to apply to healthy athletes. A combination of CJC-1295 and ipamorelin requires evidence for the combination, rather than an argument built from separate mechanisms.

Avoid treating endogenous pathways as a safety guarantee

A compound can act on a naturally occurring signaling system and still produce unwanted effects. FDA has described safety concerns and limited information for several growth-hormone-related compounds, including ibutamoren, CJC-1295 and ipamorelin. Those concerns should be read with their route and study context intact. FDA safety concerns for nominated compounding substances

AXON’s comparison does not identify a preferred wellness protocol. It asks whether the evidence connects biological activity to a meaningful benefit and adequately characterizes harm. When the available result is a biomarker change, the article should call it a biomarker change.

That discipline prevents a mechanistic explanation from being mistaken for a clinical recommendation or an assurance that a research product is appropriate for unsupervised use.